Human metapneumovirus (hMPV) is a newly recognized pathogen that like its better-known
relative, human respiratory syncytial virus (hRSV), appears to be ubiquitous and an
important cause of respiratory disease in diverse subpopulations. No antivirals or vaccines
are currently approved for the treatment or prevention of hMPV infections. However, ribavirin
is licensed to treat serious hRSV-induced infections in children and immune globulin
designed for intravenous administration (IVIG) and palivizumab (Synagis™), a humanized …

Human metapneumovirus (hMPV) is a recently elucidated respiratory virus pathogen for
which there are no agents currently licensed to prevent or treat infections caused by it.
However, NMSO3 has been reported to inhibit replication of human respiratory syncytial
virus (hRSV), a virus that is closely related to hMPV, both in vitro in tissue culture cells and in
vivo in cotton rats. For this reason, experiments were performed to compare the antiviral
activity of NMSO3 against both hRSV and hMPV in tissue culture-based assays. Heparin …